The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...

GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets ...

North America severe asthma market is set for growth, driven by high asthma prevalence, increased awareness, and advanced treatment options for severe cases. Ankush Nikam Future Market Insights, Inc.

GSK (NYSE:GSK) has received Chinese regulatory approval for its drug Nucala, also known as mepolizumab, for the treatment of ...

If approved, depemokimab would be a companion and successor to Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma and various other indications that made sales of ...

The antibody is a follow-up to the company's once-monthly IL-5 inhibitor Nucala (mepolizumab), which has been on the market since 2015. Nucala is approved for four indications, namely severe ...

The European stock markets closed mostly lower in Friday trading as The Stoxx Europe fell 0.49%, Germany's DAX dropped 0.58%, the FTSE in London was down 0.44%, France's CAC shed 1.51%, while the ...

EU Mid-Market Update: Traders primed to return with full force next week as January road ahead highlighted by Trumps return to office and beginning of Q4 earnings season; House Speaker vote in few ...